Nanoparticles offer promise for improved drug delivery in breast cancer

Nanotechnology is expected to provide major breakthroughs in how drugs cross the blood-brain barrier and reach into tumors.  That promise is already starting to be seen.

Research by Julia Ljubimova and her team at Cedars-Sinai Medical Center was recently published in the AACR journal, Cancer Research. They showed that biodegradable nanoparticles containing trastuzumab (herceptin), dramatically reduced HER2/neu protein activity in mice containing human HER2/neu positive breast tumors.

As Sally Church in her thoughtful post about this research on Pharma Strategy Blog, states, “it will be most interesting to see if this idea is developed clinically in human trials and whether the results will be reproducible or not.”

Nanotechnology and the development of nanoparticles that deliver drugs more effectively and with less toxicity, is an area that all new products professionals should be watching.

, , , , , , , , , , , , , , , , , , , ,

error: Content is protected !!